FTC Overturns Approval of $7 Billion Illumina-Grail Deal
It’s probably too late to put the champagne back in the bottle. Some six months after biotech giant Illumina gained regulatory approval for its $7 billion acquisition of cancer-screening company Grail, the Federal Trade Commission is stepping in to overturn…
